142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

299442
Facilitating access to free diabetic retinal exams with a novel geospatial approach in a national Medicare Advantage population with diabetes

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Monday, November 17, 2014 : 12:30 PM - 12:50 PM

Gilbert Haugh, MS , Clinical Analytics, Humana Inc., Louisville, KY
Esther Bae, BS, MPH , Clinical Analytics, Humana Inc., Louisville, KY
Richard Kwong, A.B, SM , Clinical Analytics, Humana Inc., Louisville, KY
Kristen Augspurger, BS , Proactive Care Strategies, Humana Inc., Louisville, KY
Vipin Gopal, Ph.D, MBA , Clinical Analytics, Humana Inc., Louisville, KY
PURPOSE:

Evaluate the effectiveness of tailoring call-to-action letters with information on in-network vision care providers closest to a person’s home on the uptake of diabetic retinal exams (DRE) in a Medicare Advantage population.

METHODS:

Study participants with diabetes and eligible to receive a free DRE in 2012 (n=17,050) were identified from a national Medicare Advantage population. Participants had comprehensive eye benefits and were residents in one of twenty pre-selected metropolitan counties. One-third of participants were randomized to receive a standard call-to-action letter with a phone number to contact their insurer to set up an appointment. Another third were randomized to receive a geospatial call-to-action letter, which had contact and address information for up to three in-network vision care providers within a 15-mile radius of the participant’s address. Call-to-action letters were sent in May 2012. The control group received standard care without any letters. Differences in DRE rates were assessed after 7 months using chi-square analysis.

RESULTS:

DRE rates differed across the three groups (P=0.034), with highest DRE rate in the geospatial letter group (48.9%), followed by the standard letter group (46.9%), and the control group (46.2%).  The geospatial group had significantly higher DRE rates than the standard (P=0.044) and control groups (P=0.007).  There was no significant difference between the standard and control groups (P=0.487).

CONCLUSION:

Tailored call-to-action letters with information about local in-network providers were more effective in increasing DRE rates than standard letters. The convenience of having nearby providers identified may help members take action and receive their DRE.

Learning Areas:

Administer health education strategies, interventions and programs
Chronic disease management and prevention
Implementation of health education strategies, interventions and programs
Planning of health education strategies, interventions, and programs
Program planning
Public health or related education

Learning Objectives:
Discuss the effects of standard letters versus targeted geospatial letters on DRE screening rates. List three key components of a targeted geospatial letter. Identify the length of time that mailed call-to-action letters are effective in increasing DRE screening rates. Describe the challenges associated with creating geospatial call-to-action letters. Design a successful call-to-action campaign using a geospatial approach.

Keyword(s): Diabetes, Vision Care

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have a degree in Mathematics, Statistics and addititional coursework in biostatistics. I have 8 years experience working with the CDC and another 8 years of clincal trials statistical work with the University of Louisville. Co-author on several papers and statistician on several NIH grants. Currently I am a strategic consultant leading a analytics team with Humana Inc. in the Clinical Analytics department.
Any relevant financial relationships? Yes

Name of Organization Clinical/Research Area Type of relationship
Humana, Inc. Clinical Analytics Employment (includes retainer)

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.